 Braxia Scientific Corp CSE:BRAX OTCMKTS:BRAXF FRA:496 CEO Roger McIntyre saw his research into the clinical uses of ketamine and esketamine published in the prestigious American Journal of Psychiatry. McIntyre and Braxias medical director Joshua Rosenblat led a team of 26 experts to develop the International Expert Opinion and Implementation Guidance Guidelines for the clinical use of rapid-acting Ketamine and Esketamine for treatment-resistant depression, according to Braxia. 